PROLOR Biotech, Inc. announced that the US Patent and Trademark Office (PTO) has allowed a new patent for the company’s veterinary version of its long-acting CTP-enhanced Non-human Growth Hormone (NhGH-CTP). The patent covers the composition of PROLOR’s proprietary pharmaceutical non-human growth hormone as well as certain associated methods of use for veterinary applications.

“This new patent covering CTP-enhanced non-human growth hormone represents another layer of protection in our CTP intellectual property portfolio and expands its scope to cover potential veterinary uses,” said Shai Novik, president of PROLOR. “In addition, we have several other patent applications that are currently pending for other CTP-enhanced long-acting therapeutic proteins and peptides. We are confident that our growing CTP patent estate will provide excellent protection for both our compounds in development and our innovative and versatile platform technology, and we believe it will serve as an important value driver for PROLOR in the future.”

PROLOR Biotech, Inc. is a clinical stage biopharmaceutical company applying unique technologies, including its patented CTP technology and its Reversible Pegylation technology, primarily to develop longer-acting, proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales.